Vital Signs - 5 June 2006


USD 1,500.00

* Required Fields

USD 1,500.00


Be the first to review this product

This issue of Vital Signs, released on June 5, 2006, provides a strategic overview of the potential impact of Medicare cuts on the oxygen therapy market. Additionally, an emerging company profile is provided on Inogen, a company that is redefining oxygen therapy. Reimbursement and regulatory news from the FDA and CMS are also provided for the week of May 17 - May 25, 2006.

Table of Contents

Vital Signs - 5 June 2006Medicare Reimbursement Cuts Threaten Oxygen Therapy MarketMedicare Reimbursement Cuts Threaten Oxygen Therapy Market

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.